{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:29Z","timestamp":1788883709571,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2003,12,30]],"date-time":"2003-12-30T00:00:00Z","timestamp":1072742400000},"content-version":"vor","delay-in-days":1124,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"PHRC, Assistance Publique-H\u00f4pitaux de Paris","award":["AOM 96045"],"award-info":[{"award-number":["AOM 96045"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Ursodeoxycholic acid (UDCA) is the only approved treatment for primary biliary cirrhosis (PBC). However, the benefit from UDCA therapy on the progression of PBC from its early stage towards extensive fibrosis and cirrhosis has not been clearly shown. The aim of this study was to assess the effect of UDCA therapy on liver fibrosis progression in PBC. A Markov model was used to analyze the progression rates between early and late histologic stages in 103 patients with PBC enrolled in a randomized, double\u2013blind, placebo\u2013controlled trial of UDCA. Early stage was defined by the presence of portal and periportal lesions without extensive fibrosis, whereas late stage was defined by the presence of numerous septa, bridging fibrosis, or cirrhosis. A total of 162 pairs of liver biopsy specimens were studied. The model accurately described the observed data. UDCA therapy was associated with a 5\u2013fold lower progression rate from early stage disease to extensive fibrosis or cirrhosis (7% per year under UDCA vs. 34% per year under placebo,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.002), but was not associated with a significant difference in regression rates (3% per year under both UDCA and placebo). At 4 years, the probability of UDCA\u2013treated patients to remain in early stage disease is 76% (95% confidence interval: 58%\u201388%), as compared with 29% (15%\u201352%) in placebo\u2013treated patients. In conclusion, UDCA therapy significantly delays the progression of liver fibrosis in PBC. Markov modeling should prove useful in assessing the efficacy of future medical treatments in clinical trials involving histologic endpoints.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1053\/jhep.2000.20240","type":"journal-article","created":{"date-parts":[[2005,2,10]],"date-time":"2005-02-10T03:51:33Z","timestamp":1108007493000},"page":"1196-1199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":275,"title":["The Effect of Ursodeoxycholic Acid Therapy on Liver Fibrosis Progression in Primary Biliary Cirrhosis"],"prefix":"10.1097","volume":"32","author":[{"given":"Christophe","family":"Corpechot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Bonnand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e Eug\u00e9nie","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Poupon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1053\/jhep.2000.20240-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis.","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/jhep.2000.20240-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2000.20240-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2000.20240-BIB4|cit4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2000.20240-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/hep.510290603","article-title":"Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis","volume":"29","author":"Poupon","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2000.20240-BIB6|cit6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/gut.36.6.935","article-title":"Characterisation of patients with a complete biochemical response to ursodeoxycholic acid","volume":"36","author":"Jorgensen","year":"1995","journal-title":"Gut"},{"key":"10.1053\/jhep.2000.20240-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis.","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1053\/jhep.2000.20240-BIB8|cit8","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2000.20240-BIB9|cit9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial","volume":"32","author":"Pares","year":"2000","journal-title":"J Hepatol"},{"key":"10.1053\/jhep.2000.20240-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/0016-5085(95)90696-7","article-title":"A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid","volume":"108","author":"Vuoristo","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2000.20240-BIB11|cit11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2000.20240-BIB12|cit12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0272989X8300300403","article-title":"The Markov process in medical prognosis","volume":"3","author":"Beck","year":"1983","journal-title":"Med Decis Making"},{"key":"10.1053\/jhep.2000.20240-BIB13|cit13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1097-0142(19940115)73:2<336::AID-CNCR2820730217>3.0.CO;2-W","article-title":"Application of multistage Markov modeling to malignant melanoma progression","volume":"73","author":"Wanek","year":"1994","journal-title":"Cancer"},{"key":"10.1053\/jhep.2000.20240-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1002\/sim.4780141804","article-title":"Multi-state models and diabetic retinopathy","volume":"14","author":"Marshall","year":"1995","journal-title":"Stat Med"},{"key":"10.1053\/jhep.2000.20240-BIB15|cit15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/hep.510230108","article-title":"Time course of histological progression in primary biliary cirrhosis","volume":"23","author":"Locke","year":"1996","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2000.20240-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.510290444","article-title":"Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression","volume":"29","author":"Degott","year":"1999","journal-title":"Hepatology"},{"key":"10.1053\/jhep.2000.20240-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/0016-5085(85)90001-0","article-title":"Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients","volume":"88","author":"Portmann","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1053\/jhep.2000.20240-BIB18|cit18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2307\/2530699","article-title":"A Markov model for analysing cancer markers and disease states in survival studies","volume":"42","author":"Kay","year":"1986","journal-title":"Biometrics"},{"key":"10.1053\/jhep.2000.20240-BIB19|cit19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/sim.4780080708","article-title":"Statistical analysis of the stages of HIV infection using a Markov model","volume":"8","author":"Longini","year":"1989","journal-title":"Stat Med"},{"key":"10.1053\/jhep.2000.20240-BIB20|cit20","first-page":"1257","article-title":"Primary biliary cirrhosis","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc R Soc Med"},{"key":"10.1053\/jhep.2000.20240-BIB21|cit21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch [Pathol Anat]"},{"key":"10.1053\/jhep.2000.20240-BIB22|cit22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/jcp.49.7.556","article-title":"Accuracy of staging in primary biliary cirrhosis","volume":"49","author":"Garrido","year":"1996","journal-title":"J Clin Pathol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjhep.2000.20240","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjhep.2000.20240","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200012000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T06:22:47Z","timestamp":1733034167000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200012000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000]]}},"URL":"https:\/\/doi.org\/10.1053\/jhep.2000.20240","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}